Page results
-
UCLH has continued to achieve excellent results in the National Inpatient Survey, with patients rating their overall care as 8.7 out of 10 – the top score amongst our London peers.
-
This page has been written for patients who are having radioactive iodine (131I) ablation and/or radioiodine treatment for thyroid cancer.
-
UCLH Charity is delighted to announce that the Dangoor Family’s Exilarch’s Foundation has pledged a £1.2m gift to support the next phase of the development of the CAR T programme at University College London Hospitals NHS Foundation Trust (UCLH). The CAR T Speed Release Project aims to reduce the time between extracting patient’s stem cells and injecting re-engineered CAR T cells back into patients with cancer to fight cancer cells.
-
Patient information for Red Cell Network patients
-
Education and training videos for Red Cell Network patients
-
The Sickle Cell Society (SCS) and the UK Thalassaemia Society (UKTS) have worked in partnership with the NHS sickle cell and thalassaemia (SCT) screening programme to engage with communities less likely to access health information through usual NHS channels. The societies provide feedback from people that share the same population background or have experience of the condition and to feed into the programme updates and improvements.
-
An immunotherapy drug given before surgery instead of chemotherapy meant that significantly more patients with a certain genetic profile were cancer free after surgery, according to clinical trial results presented by researchers at UCL and UCLH.
-
Your treatment for acute lymphoblastic leukaemia (ALL) will be delivered within a number of comprehensive specialised services led by medical and nursing cancer care experts.
-
Acute lymphoblastic leukaemia (ALL) is a form of cancer that affects the cells in the bone marrow, the soft material inside your bones.
-
This information explains brain stem death and the tests used to confirm the diagnosis. It aims to answer frequently asked questions.
File results
-
FOI/2024/0417 - Funding for point-of-care home blood monitoring devices for cancer patients
-
FOI/2024/0420 - Commercialisation of NHS patient data
-
FOI/2024/0421 - Capital staffing nurses/ approved framework agencies/ escalated rates
-
FOI/2024/0423 - Giant cell arteritis (GCA) patient treatment
-
FOI/2024/0425 - Freedom of Information (FOI) structure, banding and job titles
-
FOI/2024/0426 - Agency staff spend for nursing, HCAs, pharmacists, occupational therapists and physiotherapists
-
FOI/2024/0439 - Digital dictation provider
-
FOI/2024/0450 - Trust-wide obesity and weight management strategy
-
FOI/2024/0440 - Patient reported outcome measures (PROMs) in oncology
-
FOI/2024/0416 - Home dialysis treatment